Esomeprazole Magnesium

ESOMEPRAZOLE MAGNESIUM- esomeprazole magnesium capsule, delayed release pellets
Bryant Ranch Prepack

Figure 1Figure 2: Maintenance of Healing Rates by Month (Study 177)Figure 3: Maintenance of Healing Rates by Month (Study 178)Figure 4Figure 5

1 INDICATIONS AND USAGE

1.1 Healing of Erosive Esophagitis (EE)

Adults

Esomeprazole Magnesium Delayed-release Capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of Esomeprazole Magnesium Delayed-release Capsules may be considered.

Pediatric Patients 12 Years to 17 Years of Age

Esomeprazole Magnesium Delayed-release Capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age.

Pediatric Patients 1 Year to 11 Years of Age

Esomeprazole Magnesium is indicated for the short-term treatment (8 weeks) for the healing of EE in pediatric patients 1 year to 11 years of age.

1.2 Maintenance of Healing of EE

Esomeprazole Magnesium Delayed-release Capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months.

1.3 Treatment of Symptomatic GERD

Adults

Esomeprazole Magnesium Delayed-release Capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults.

Pediatric Patients 12 Years to 17 Years of Age

Esomeprazole Magnesium Delayed-release Capsules are indicated for short-term treatment (4 weeks) of heartburn and other symptoms associated with GERD in pediatric patients 12 years to 17 years of age.

Pediatric Patients 1 Year to 11 Years of Age

Esomeprazole Magnesium is indicated for short-term treatment (up to 8 weeks) of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age.

1.4 Risk Reduction of Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Associated Gastric Ulcer

Esomeprazole Magnesium Delayed-release Capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in adult patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age (60 years and older) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months.

1.5 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

Triple Therapy

Esomeprazole Magnesium Delayed-release Capsules in combination with amoxicillin and clarithromycin is indicated for the treatment of adult patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori.

In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the prescribing information for clarithromycin].

1.6 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome

Esomeprazole Magnesium Delayed-release Capsules are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome, in adults.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage in Adults by Indication

Table 1 shows the recommended adult dosage of Esomeprazole Magnesium Delayed-release Capsules by indication.

The duration of Esomeprazole Magnesium Delayed-release Capsules treatment should be based on available safety and efficacy data specific to the defined indication and dosing frequency and individual patient medical needs. Esomeprazole Magnesium Delayed-release Capsules should only be initiated and continued if the benefits outweigh the risks of treatment.

Table 1: Recommended Dosage of Esomeprazole Magnesium Delayed-release Capsules in Adults by Indication

Adult Indication

Recommended Dosage of Esomeprazole Magnesium

Delayed-release Capsules

Treatment Duration
Healing of EE 20 mg or 40 mg1 once daily1 4 to 8 weeks2
Controlled studies do not extend beyond 6 months
Maintenance of Healing of EE 20 mg once daily
Treatment of Symptomatic GERD 20 mg once daily 4 weeks; if symptoms do not resolve completely, consider an additional 4 weeks
Risk Reduction of NSAID-Associated Gastric Ulcer

20 mg or 40 mg1 once daily

Controlled studies do not extend beyond 6 months
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence (Triple Therapy) Esomeprazole Magnesium Delayed-release Capsules 40 mg once daily1 10 days
Amoxicillin 1000 mg twice daily3 10 days

Clarithromycin 500 mg twice daily3

10 days

Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome

Starting dosage is 40 mg twice daily4 ; individualize the regimen to patient needs.

Dosages of up to 240 mg/day have been

administered [see Clinical Studies (14.7)].

As long as clinically

1. A maximum dosage of 20 mg once daily is recommended for patients with severe liver impairment (Child-Pugh Class C) [see Use in Specific Populations (8.6) ].

2. Most patients are healed within 4 to 8 weeks. For patients who do not heal after 4 to 8 weeks, an additional 4 to 8 weeks of treatment may be required to achieve healing [see Clinical Studies (14.1) ].

3. Refer to the amoxicillin and clarithromycin prescribing information for dosage adjustments in elderly and renally-impaired patients.

4. A starting dosage of 20 mg twice daily is recommended for patients with severe liver impairment (Child-Pugh Class C) [see Use in Specific Populations (8.6)].

2.2 Recommended Dosage in Pediatric Patients by Indication

Table 2 shows the recommended dosage of Esomeprazole Magnesium Delayed-release Capsules in pediatric patients by indication.

Table 2: Recommended Dosage of Esomeprazole Magnesium Delayed-release Capsules in Pediatric Patients by Indication

Indication Patient Age Recommended Dosage Duration
Healing of EE 12 years to 17 years

Esomeprazole Magnesium Delayed-release Capsules:

4 to 8 weeks
1 year to 11 years1 Esomeprazole Magnesium:

Less than 20 kg

10 mg once daily

20 kg and greater

8 weeks

Treatment of Symptomatic

12 years to 17 years

Esomeprazole Magnesium Delayed-release Capsules:

4 weeks
1 year to 11 years

Esomeprazole Magnesium:

1
Up to 8 weeks

1 Dosages over 1 mg/kg/day have not been studied

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.